Endothelin-1 causes arteriolar dilation by stimulating endogenous nitric oxide production, which attenuates its constrictor effects on small resistance vessels in striated muscle.
Answers are grounded in this paper and cite their sources.
No change to clinical vascular management; leaves open endothelin-1/NO crosstalk relevance in human resistance vessels.
Previous studies demonstrated that endothelin-1 is a potent vasoconstrictor in the microcirculation. In this study, we assessed the ability of endothelin-1 to induced dilation of small arterioles in the rat cremaster muscle. Responses to topical application of endothelin-1 were assessed by using intravital microscopy. Exposure to increasing concentrations of endothelin-1 (10[-13]-10[-8] M) produced a dose-dependent constriction of third-order arterioles (20 +/- 1.4 microm). Pretreatment with hydroquinone (HQ) or N omega-nitro-L-arginine methyl ester (L-NAME), antagonists of nitric oxide production, caused a significant potentiation in the reactivity of third-order arterioles to endothelin-1. In addition, we observed a significant vasodilation to low levels of endothelin-1 (10[-14]-10[-12] M) in the presence of the endothelin type-A receptor (ET-A) antagonist, BQ123. This dilation was abolished in the presence of a 10(-4) M bath concentration of L-NAME. These results indicated that endothelin-1 caused arteriolar dilation by stimulating endogenous production of nitric oxide. This effect appeared to attenuate the constrictor effects of endothelin-1 on small resistance vessels in striated muscle.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: